Locations:

Abu Dhabi|Canada|Florida|London|Nevada|Ohio|

Search

Tag: left atrial appendage occlusion (LAAO)

medical device deployed in the heart's left atrial appendage

November 18, 2024/Heart, Vascular and Thoracic/Electrophysiology

LAA Occlusion Compares Favorably With Newer Oral Anticoagulants After AF Ablation

OPTION trial demonstrates significantly less bleeding risk with comparable efficacy

Watchman FLX device for LAA occlusion

September 13, 2024/Heart, Vascular and Thoracic/Electrophysiology

Real-World Experience With WATCHMAN FLX Replicates Pivotal Trial Outcomes

Large SURPASS registry study finds LAAO device safe and effective through one year

illustration of the human heart focused on the left atrial appendage

March 12, 2024/Heart, Vascular and Thoracic/Cardiac Surgery

Takeaways From Updated STS Guidelines for Surgical Treatment of Atrial Fibrillation

Concomitant AF ablation and LAA occlusion strongly endorsed during elective heart surgery

23-HVI-4298710_LAAO+TAVR_650x450

October 24, 2023/Heart, Vascular and Thoracic/Interventional Cardiology

Concurrent TAVR and Watchman Placement Is Noninferior to TAVR Plus Medical Therapy for Atrial Fibrillation

Randomized WATCH-TAVR trial confirms safety of the combined procedures

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

illustration of heart and lungs with text

May 4, 2023/Heart, Vascular and Thoracic/Outcomes

Vital Stats From Our Heart Failure and Electrophysiology Programs

Our latest volume and outcomes data in two key subspecialty areas

Boston Scientific Corporation WATCHMAN FLX Device

March 15, 2023/Heart, Vascular and Thoracic/Electrophysiology

Watchman FLX at 1 Year: Real-World Performance Consistent With Trial Results

Large SURPASS registry study confirms high seal rates, acceptable safety

The Featured Image for the post

March 16, 2022/Heart, Vascular and Thoracic/Electrophysiology

SURPASS Study Confirms Real-World Safety and Efficacy of Watchman FLX Through 45 Days

Interim report from large registry analysis compares favorably with pivotal trial

19-HRT-062-watchman-650×450

April 9, 2019/Heart, Vascular and Thoracic/Affiliations & Alliances

Launching an LAAO Program: How Cleveland Clinic Assisted an Affiliated Institution

A Missouri center turns lessons from a site visit into program success

BackPage 1 of 1Next

Advertisement

Ad